<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Pain</journal-id><journal-id journal-id-type="iso-abbrev">Korean J Pain</journal-id><journal-id journal-id-type="publisher-id">KJP</journal-id><journal-title-group><journal-title>The Korean Journal of Pain</journal-title></journal-title-group><issn pub-type="ppub">2005-9159</issn><issn pub-type="epub">2093-0569</issn><publisher><publisher-name>The Korean Pain Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28757917</article-id><article-id pub-id-type="pmc">5532524</article-id><article-id pub-id-type="doi">10.3344/kjp.2017.30.3.176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baratloo</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mirbaha</surname><given-names>Sahar</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Delavar Kasmaei</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Payandemehr</surname><given-names>Pooya</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elmaraezy</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Negida</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Emergency Medicine, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="A2"><label>2</label>Department of Emergency Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</aff><aff id="A3"><label>3</label>Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</aff><aff id="A4"><label>4</label>Faculty of Medicine, Al Azhar University, Cairo, Egypt.</aff><aff id="A5"><label>5</label>Medical Research Group of Egypt, El-Sharkia, Egypt.</aff><aff id="A6"><label>6</label>Faculty of Medicine, Zagazig University, El-Sharkia, Egypt.</aff><author-notes><corresp>Correspondence to: Ahmed Negida. Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia 44519, Egypt. Tel: +201125549087, <email>ahmed01251@medicine.zu.edu.eg</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>30</day><month>6</month><year>2017</year></pub-date><volume>30</volume><issue>3</issue><fpage>176</fpage><lpage>182</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>26</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; The Korean Pain Society, 2017</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Current evidence suggests that intravenous magnesium sulfate might be effective for reducing migraine pain. In a recent pilot study, we showed that intravenous caffeine citrate could reduce the severity of migraine headache. The objective of this study is to investigate the efficacy of intravenous caffeine citrate vs. magnesium sulfate for management of acute migraine headache.</p></sec><sec><title>Methods</title><p>We conducted a prospective quasi-experimental study from January until May 2016 in two educational medical centers of Shahid Beheshti University of Medical Sciences (Shoahadaye Tajrish Hospital and Imam Hossein Hospital), Tehran, Iran. The study included patients who were referred to the emergency department and met the migraine diagnosis criteria of the International Headache Society. Patients were allocated into 2 groups receiving either 60 mg intravenous caffeine or 2 g intravenous magnesium sulfate. The pain scores, based on the visual analog scale, were recorded on admission, as well as one and two hours after receiving the drug. A Chi-Square test and student t-test were used for analysis of baseline characteristics. A Mann-Whitney U test and Wilcoxon singed rank test were used to analyze differences in the visual analogue scale (VAS) score between and within the groups respectively.</p></sec><sec><title>Results</title><p>In total, 70 patients (35 patients in each group) with the mean age of 33.1 &#x000b1; 11.3 years were included (64.3% female). For the Caffeine citrate group, the median pain score decreased from 9.0 (2.0) to 5.0 (4.0) after one hour and to 3.0 (4.0) after two hours. For the magnesium sulfate group, the pain score decreased from 8.0 (2.0) to 2.0 (2.0) after one hour and to 0.0 (1.0) after two hours. Both intravenous caffeine citrate and intravenous magnesium sulfate reduced pain scores significantly but the magnesium sulfate group showed more improvement than the Caffeine citrate group after one hour (<italic>P</italic> &#x0003c; 0.001) and after two hours (<italic>P</italic> &#x0003c; 0.001).</p></sec><sec><title>Conclusions</title><p>It is likely that both intravenous caffeine and intravenous magnesium sulfate can reduce the severity of migraine headache. Moreover, intravenous magnesium sulfate at a dose of 2 g might be superior to intravenous caffeine citrate 60 mg for the short term management of migraine headache in emergency departments.</p></sec></abstract><kwd-group><kwd>Caffeine citrate</kwd><kwd>Emergency department</kwd><kwd>Headache</kwd><kwd>Magnesium sulfate</kwd><kwd>Migraine disorders</kwd><kwd>Pain management</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Migraine is a prevalent, debilitating neurological condition that lacks a universally effective therapy. It is characterized by attacks of throbbing, unilateral pain associated with nausea, vomiting, phonophobia, and photophobia [<xref rid="B1" ref-type="bibr">1</xref>].</p><sec><title>1. Current treatments of migraine</title><p>Migraine treatment in emergency departments presents a clinical appeal for both patients and health care providers. Patients' response to medications is widely idiosyncratic and treatment agents that were effective in one patient might fail in another apparently similar case. Therefore, the treatment must be tailored to each individual case. The mainstays of current migraine management options include non-steroidal anti-inflammatory drugs (NSAIDs) and triptans [<xref rid="B2" ref-type="bibr">2</xref>]. NSAIDs are used for mild to moderate attacks of migraine as well as acetaminophen, which is proven to be effective for attacks of moderate severity [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>]. Unfortunately, NSAIDs have a short half-life; therefore, repeated administration may be needed on a single attack of migraine and adverse effects like tight throat and flushing are common [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref>]. Triptans are usually prescribed for severe attacks not responding to the NSAIDs/acetaminophen strategy [<xref rid="B5" ref-type="bibr">5</xref>]. However, the associated side effects limit their prescription in the clinic. The combination of analgesics with tramadol, barbiturates, or stronger opioids, like morphine, is restricted to exceptionally unresponsive cases. Thus safer, more tolerable, and mechanism-based treatment approaches for migraine are imperative.</p></sec><sec><title>2. Magnesium sulfate for migraine</title><p>Suboptimal magnesium level has been repeatedly reported in migraine patients [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>]. Consequently, several clinical trials investigated the efficacy and safety of parenteral and oral magnesium supplementation in acute migraine [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>]. Some studies support the use of oral magnesium for the prophylaxis of migraine [<xref rid="B15" ref-type="bibr">15</xref>].</p></sec><sec><title>3. Intravenous caffeine for migraine</title><p>Caffeine has been recommended for acute migraine treatment for hundreds of years [<xref rid="B16" ref-type="bibr">16</xref>]. Combinations of caffeine with non-opioid analgesics, ergotamine and codeine showed an abortive effect in acute episodes of migraine [<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref>]. In two recent trials, we reported that intravenous caffeine has comparable efficacy to ketorolac for ameliorating migraine pain [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>].</p><p>There is scarce data on the efficacy of intravenous caffeine citrate for reducing pain scores in patients with acute migraine. We have done some studies about the role of caffeine for pain management in acute migraine headache [<xref rid="B16" ref-type="bibr">16</xref>]. We have assessed its efficacy as a sole treatment and also compared it with ketorolac [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. To the best of our knowledge, there is not any study that uses intravenous caffeine in this regard, except for those belonging to Baratloo et al. [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. To further these investigations, in the current study, we performed prospective research to assess the efficacy of intravenous caffeine citrate vs. magnesium sulfate for management of acute migraine headache.</p></sec></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>1. Study design and setting</title><p>This was a prospective quasi-experimental study that was conducted from January until May 2016 in two educational medical centers at Shahid Beheshti University of Medical Sciences (Shoahadaye Tajrish Hospital and Imam Hossein Hospital), Tehran, Iran. Patients with a chief complaint of moderate to severe headache presenting to the emergency department were considered for this study. For patient enrolment, we used the same strict inclusion and exclusion criteria reported in our previous pilot study [<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec><title>2. Definition</title><p>The visual analog scale (VAS) is a measurement tool used to quantify the pain score. VAS is a continuous scale comprised of a horizontal or vertical line, usually 10 centimeters (100 mm) in length. In the current study we considered 10 as the highest possible VAS score. In this measurement scale, &#x0201c;no pain&#x0201d; was defined as a score of 0 and &#x0201c;pain as bad as it could be&#x0201d; or &#x0201c;the worst imaginable pain&#x0201d; was considered as a score of 10 [<xref rid="B22" ref-type="bibr">22</xref>].</p></sec><sec><title>3. Study population</title><p>Patients who referred to the emergency department were deemed eligible and included in the study if they met the following criteria: 1) their age ranged from 18 to 60 years old; 2) their complaint of migraine pain fulfilled the criteria of a common migraine based on the International Headache Society Criteria and they had had migraines for at least a year prior to the admission day [1]; and 3) their VAS pain score indicated severe or moderate pain (VAS pain score &#x02265; 4) [<xref rid="B23" ref-type="bibr">23</xref><xref rid="B24" ref-type="bibr">24</xref>].</p><p>We excluded patients who had, at least, one of the following items: 1) a history of any cardiac dysrhythmia; 2) hypertension; 3) ischemic heart disease; 4) active peptic ulcer disease; 5) inflammatory bowel disease; 6) pregnancy; 7) were breast feeding; 8) coagulopathy; 9) renal failure; 10) hepatic failure; or 11) a sleep disorder.</p><p>The sample size was calculated to detect a change of at least 3 cm in the VAS scale; considering &#x003b2; = 0.01 and &#x003b1; = 0.05, the minimum sample size for the study was estimated to be 35 subjects in each group.</p></sec><sec><title>4. Intervention</title><p>Those presenting to the emergency department of Shohadaye Tajrish Hospital received a 60 mg caffeine citrate intravenous infusion within about 10 minutes. Those referring to the Imam Hossein Hospital received an intravenous infusion of 2 g magnesium sulfate. Both drugs were diluted in 100 cc normal saline 0.9% and infused over 10 minutes. All patients were monitored for any possible side effects. If any adverse effects (tachycardia, hypertension, itching, nausea and vomiting, pain at the injection site, irritability) happened, the process had to be stopped. At one and two hours after drug administration, patients were asked about their pain score on the VAS scale. A decrease of more than 3 points on the pain scale was considered a proper response [<xref rid="B25" ref-type="bibr">25</xref>].</p></sec><sec><title>5. Statistical analysis</title><p>Statistical analysis was performed using SPSS version 22. For describing continuous variables and mean, standard deviation, median, and inter-quartile range were used. The Chi-Square test and student t-test were used for analysis of baseline characteristics. The Mann-Whitney U test and Wilcoxon signed rank test were used to analyze differences in VAS pain scores. A <italic>P</italic> value &#x02264; 0.05 was considered significant.</p></sec><sec><title>6. Ethical considerations</title><p>The study was performed with a strict commitment to ethical considerations of the Declaration of Helsinki. All eligible patients were informed about the new drug, and all gave a signed informed consent. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran. This study is registered in the Iranian Registry of Clinical Trials (<ext-link ext-link-type="uri" xlink:href="http://www.irct.ir">www.irct.ir</ext-link>) under the code IRCT2016061315640N2.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Seventy patients were enrolled in the study. Their mean age was 33.1 &#x000b1; 11.3 years. Forty-five of the patients (64.3%) were female and 25 (35.7%) were male. Baseline characteristics of the patients in the two groups are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Age and gender were significantly different in the two studied groups.</p><p>For the Caffeine citrate group, the median (interquartile range (IQR)) of the VAS pain score decreased significantly from 9.0 (2.0) to 5.0 (4.0) after one hour and to 3.0 (4.0) after two hours. For the Magnesium Sulfate group, the VAS pain score decreased significantly from 8.0 (2.0) to 2.0 (2.0) after one hour and to 0.0 (1.0) after two hours (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p>The VAS pain score decreased more in the Magnesium sulfate group compared to the Caffeine citrate group after one hour (<italic>P</italic> &#x0003c; 0.001) and two hours (<italic>P</italic> &#x0003c; 0.001).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>1. Major pathophysiology of migraine</title><p>Headache is the most important and most common manifestation of migraine. Due to the pulsating nature of the headache, the pathophysiology of migraine was attributed to vascular problems in the brain for many years. The vascular theory for explaining migraine, which was considered valid until the middle of the 20<sup>th</sup> century, was based on 3 observations: 1) observations reported by 2 researchers named Ray and Wolff during a neurosurgical operation on a conscious patient in 1940; 2) inflation of carotid and extracranial arteries and seeing them pulsating during migraine headache attacks; 3) effectiveness of ergotamine, which is a powerful vasoconstrictor, for treating migraines [<xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">27</xref>]. Currently, previous theories are questioned and more thorough investigations are being carried out on this topic. Modern imaging methods have shown that changes in vascular diameters are not proportionate with pain severity and response to treatment [<xref rid="B28" ref-type="bibr">28</xref><xref rid="B29" ref-type="bibr">29</xref><xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">31</xref>]. It seems that at the beginning of the headache vasodilation has not occurred yet, raising the question about the role of vasodilation in the pathophysiology of this disorder [<xref rid="B32" ref-type="bibr">32</xref>]. Therefore, migraine is not a primary vascular event and it seems that stimulation of trigeminal nerve branches as well as parasympathetic nerves following a series of activities in the brain's cortex (cortical spreading depression) leads to reactions in the meninges and brain stem that can explain migraine symptoms [<xref rid="B33" ref-type="bibr">33</xref>]. Disorders in the function of aminergic brain stem nuclei result in vasodilation and an increase in severity of pain through a series of reactions, and vasodilation brings about other neurogenic reactions. The close relationship of the vessels in the meninges with the trigeminal nerve branches helps in a better understanding of these events [<xref rid="B34" ref-type="bibr">34</xref>].</p></sec><sec><title>2. Efficacy of studied agents</title><p>The results of this study showed that both intravenous magnesium sulfate and intravenous caffeine citrate could be considered for treatment of acute migraine headache. However, magnesium sulfate caused a more significant reduction of the VAS pain score compared to caffeine citrate at one and two hours after administration. However, there was a significant difference in age and sex between the studied groups that could be &#x0201c;confounding factors&#x0201d;.</p></sec><sec><title>3. Safety of treatment</title><p>There were no cases of withdrawal or intolerance to the treatment, which indicates the safety of intravenous caffeine citrate and magnesium sulfate in the studied population. There was not any serious adverse event in the studied population throughout the duration of hospitalization. However, this should be interpreted cautiously due to the short period of observation and the strict inclusion and exclusion criteria for selecting eligible subjects.</p></sec><sec><title>4. Explanation of results</title><p>The molecular mechanism behind migraine has not yet been understood. However, the literature suggests multiple underlying mechanisms, which allows for testing a wide range of therapeutic options. Magnesium deficiency is hypothesized to be implicated in the pathophysiology of migraine. Physiologically, magnesium inactivates excitatory N-Methyl-D-aspartate (NMDA) glutamate receptors [<xref rid="B35" ref-type="bibr">35</xref>]. Depletion of magnesium drives NMDA-coupled calcium channels towards abnormal opening, which allows increased calcium influx, causing cytotoxicity and leading to neuronal injury secondary to the generation of toxic nitric oxide radicals [<xref rid="B36" ref-type="bibr">36</xref>]. Cortical depression is another possible mechanism for initiation of migraine [<xref rid="B37" ref-type="bibr">37</xref><xref rid="B38" ref-type="bibr">38</xref>]. Magnesium deficiency affects mitochondrial oxidative phosphorylation and neuronal polarization, resulting in altered mitochondrial metabolism, which is suggested as increasing susceptibility to cortical depression [<xref rid="B39" ref-type="bibr">39</xref>]. On the other hand, the neurogenic theory suggests central sensitization or sensitization of the trigemino-vascular afferents of nociceptive neurons as a possible cause of migraine [<xref rid="B40" ref-type="bibr">40</xref><xref rid="B41" ref-type="bibr">41</xref><xref rid="B42" ref-type="bibr">42</xref>]. Caffeine acts by inhibiting adenosine receptors (A1 and A2) in the brain, which explains its marked effect as an abortive agent in migraine attacks [<xref rid="B16" ref-type="bibr">16</xref><xref rid="B43" ref-type="bibr">43</xref><xref rid="B44" ref-type="bibr">44</xref><xref rid="B45" ref-type="bibr">45</xref>].</p></sec><sec><title>5. Previous studies</title><p>A recent meta-analysis of 21 randomized clinical trials (RCT) demonstrated the favorable effects of both intravenous and oral magnesium sulfate supplementation. Intravenous magnesium sulfate reduced acute migraine attacks within 15 to 45 minutes, 120 minutes, and 24 hours after initial infusion, while oral supplementation alleviated the frequency and intensity of the attacks [<xref rid="B46" ref-type="bibr">46</xref>].</p><p>Caffeine is frequently used in combination with other analgesics. The acetaminophen/aspirin /caffeine cocktail is classified as a level one option for acute migraine attacks by the American Headache Society, whilst the combination of caffeine and ergotamine is listed as level two [<xref rid="B2" ref-type="bibr">2</xref>]. We initiated the use of caffeine as monotherapy in a pilot study followed by an RCT comparing intravenous caffeine and ketorolac [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. Both regimens showed comparable positive effect in terms of pain relief, therapeutic success, and incidence of adverse events [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec><title>6. Age and sex differences in pain and analgesia</title><p>Age and sex varied significantly between the groups in this research. The relationship of migraine pain with these characteristics is complicated and confusing. Bolay et al. [<xref rid="B47" ref-type="bibr">47</xref>] claimed that the impact of sex on migraine pain varied with age and significant changes were seen in women over 30 years old; but not in men. Sex also influences headache characteristics and migraine-associated symptoms, which vary across age groups, particularly in women. It has been reported that women have lower pain thresholds and tolerance for pain, but a superior capability to differentiate painful stimuli. In addition, sex differences in response to pain treatment have been proposed. Some have attributed such differences to sex hormones [<xref rid="B48" ref-type="bibr">48</xref><xref rid="B49" ref-type="bibr">49</xref><xref rid="B50" ref-type="bibr">50</xref>]. Age related changes such as hypothalamic-pituitary-adrenal axis dysregulation and autonomic function changes could lead to increased pain sensitivity. On the other hand, some literature suggests that pain perception diminishes in old age. It seems that existing data regarding pain and aging are limited and equivocal and further studies are needed [<xref rid="B51" ref-type="bibr">51</xref><xref rid="B52" ref-type="bibr">52</xref>]. Victor et al. [<xref rid="B53" ref-type="bibr">53</xref>] assessed age and sex specific patterns of migraine prevalence in 40892 individuals in the United States. Migraine prevalence was 2-fold higher in females (17.5% vs. 8.6%) but showed a dual peaking around the late 20s and 50 years of age in both sexes.</p></sec><sec><title>7. Strong points and limitations</title><p>Our study has several strong points: patients were diagnosed according to the migraine diagnostic criteria of the International Headache Society and the severity of pain was assessed by the VAS score, which is a common and reliable measure of pain. There are some limitations: (1) the sample size is relatively small and (2) the study did not investigate the long-term efficacy of the drugs. Lack of randomization is the most important disadvantages of quasi-randomized studies [<xref rid="B54" ref-type="bibr">54</xref>]. There are statistical differences regarding age and sex between the studied groups that might have caused a bias in this investigation.</p></sec><sec><title>8. Implications for future research</title><p>In light of the current evidence, we argue that there is no universal agreement on the treatment of acute migraine. Therefore, management of acute episodes should be individualized on a case to case basis due to the highly idiosyncratic effects of available agents. We recommend further well designed RCTs to confirm the findings of this study.</p></sec><sec><title>9. Conclusion</title><p>It is likely that both intravenous caffeine and intravenous magnesium sulfate can reduce the severity of migraine pain. Moreover, intravenous magnesium sulfate at a dose of 2 g might be superior to intravenous caffeine citrate 60 mg for short term management of migraine headaches.</p></sec></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>We would like to express our special thanks to the Emergency Department staff of Shohadaye Tajrish and Imam Hossein Hospitals, Tehran, Iran.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab><article-title>The international classification of headache disorders, 3rd edition (beta version)</article-title><source>Cephalalgia</source><year>2013</year><volume>33</volume><fpage>629</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">23771276</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmura</surname><given-names>MJ</given-names></name><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Schwedt</surname><given-names>TJ</given-names></name></person-group><article-title>The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies</article-title><source>Headache</source><year>2015</year><volume>55</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">25600718</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>MJ</given-names></name><name><surname>Codispoti</surname><given-names>JR</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name></person-group><article-title>A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache</article-title><source>Headache</source><year>2010</year><volume>50</volume><fpage>819</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">20236342</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Baggish</surname><given-names>JS</given-names></name><name><surname>Stewart</surname><given-names>WF</given-names></name><name><surname>Codispoti</surname><given-names>JR</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name></person-group><article-title>Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>3486</fpage><lpage>3492</lpage><pub-id pub-id-type="pmid">11112243</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>WJ</given-names></name></person-group><article-title>Acute migraine treatment in adults</article-title><source>Headache</source><year>2015</year><volume>55</volume><fpage>778</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">25877672</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suthisisang</surname><given-names>C</given-names></name><name><surname>Poolsup</surname><given-names>N</given-names></name><name><surname>Kittikulsuth</surname><given-names>W</given-names></name><name><surname>Pudchakan</surname><given-names>P</given-names></name><name><surname>Wiwatpanich</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis</article-title><source>Ann Pharmacother</source><year>2007</year><volume>41</volume><fpage>1782</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">17878396</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boska</surname><given-names>MD</given-names></name><name><surname>Welch</surname><given-names>KM</given-names></name><name><surname>Barker</surname><given-names>PB</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name><name><surname>Schultz</surname><given-names>L</given-names></name></person-group><article-title>Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>1227</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">11971091</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauskop</surname><given-names>A</given-names></name><name><surname>Altura</surname><given-names>BT</given-names></name><name><surname>Altura</surname><given-names>BM</given-names></name></person-group><article-title>Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">12010379</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trauninger</surname><given-names>A</given-names></name><name><surname>Pfund</surname><given-names>Z</given-names></name><name><surname>Koszegi</surname><given-names>T</given-names></name><name><surname>Czopf</surname><given-names>J</given-names></name></person-group><article-title>Oral magnesium load test in patients with migraine</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">12005285</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cete</surname><given-names>Y</given-names></name><name><surname>Dora</surname><given-names>B</given-names></name><name><surname>Ertan</surname><given-names>C</given-names></name><name><surname>Ozdemir</surname><given-names>C</given-names></name><name><surname>Oktay</surname><given-names>C</given-names></name></person-group><article-title>A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department</article-title><source>Cephalalgia</source><year>2005</year><volume>25</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">15689195</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demirkaya</surname><given-names>S</given-names></name><name><surname>Vural</surname><given-names>O</given-names></name><name><surname>Dora</surname><given-names>B</given-names></name><name><surname>Top&#x000e7;uo&#x0011f;lu</surname><given-names>MA</given-names></name></person-group><article-title>Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">11251702</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Bordini</surname><given-names>CA</given-names></name><name><surname>Tepper</surname><given-names>SJ</given-names></name><name><surname>Speciali</surname><given-names>JG</given-names></name></person-group><article-title>Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">12110110</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbo</surname><given-names>J</given-names></name><name><surname>Esses</surname><given-names>D</given-names></name><name><surname>Bijur</surname><given-names>PE</given-names></name><name><surname>Iannaccone</surname><given-names>R</given-names></name><name><surname>Gallagher</surname><given-names>EJ</given-names></name></person-group><article-title>Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache</article-title><source>Ann Emerg Med</source><year>2001</year><volume>38</volume><fpage>621</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">11719739</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;seoglu</surname><given-names>E</given-names></name><name><surname>Talaslioglu</surname><given-names>A</given-names></name><name><surname>G&#x000f6;n&#x000fc;l</surname><given-names>AS</given-names></name><name><surname>Kula</surname><given-names>M</given-names></name></person-group><article-title>The effects of magnesium prophylaxis in migraine without aura</article-title><source>Magnes Res</source><year>2008</year><volume>21</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">18705538</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teigen</surname><given-names>L</given-names></name><name><surname>Boes</surname><given-names>CJ</given-names></name></person-group><article-title>An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine</article-title><source>Cephalalgia</source><year>2015</year><volume>35</volume><fpage>912</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">25533715</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baratloo</surname><given-names>A</given-names></name><name><surname>Rouhipour</surname><given-names>A</given-names></name><name><surname>Forouzanfar</surname><given-names>MM</given-names></name><name><surname>Safari</surname><given-names>S</given-names></name><name><surname>Amiri</surname><given-names>M</given-names></name><name><surname>Negida</surname><given-names>A</given-names></name></person-group><article-title>The role of caffeine in pain management: a brief literature review</article-title><source>Anesth Pain Med</source><year>2016</year><volume>6</volume><fpage>e33193</fpage><pub-id pub-id-type="pmid">27642573</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Pfaffenrath</surname><given-names>V</given-names></name><name><surname>Pageler</surname><given-names>L</given-names></name><name><surname>Peil</surname><given-names>H</given-names></name><name><surname>Aicher</surname><given-names>B</given-names></name></person-group><article-title>The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study</article-title><source>Cephalalgia</source><year>2005</year><volume>25</volume><fpage>776</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">16162254</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Saper</surname><given-names>JR</given-names></name><name><surname>Ryan</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study</article-title><source>Headache</source><year>2006</year><volume>46</volume><fpage>444</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">16618262</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Winner</surname><given-names>PK</given-names></name><name><surname>Chmiel</surname><given-names>JJ</given-names></name></person-group><article-title>Migraine preventive medication reduces resource utilization</article-title><source>Headache</source><year>2003</year><volume>43</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">12603635</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baratloo</surname><given-names>A</given-names></name><name><surname>Bafarani</surname><given-names>SA</given-names></name><name><surname>Forouzanfar</surname><given-names>MM</given-names></name><name><surname>Hashemi</surname><given-names>B</given-names></name><name><surname>Friedman</surname><given-names>BW</given-names></name><name><surname>Abdalvand</surname><given-names>A</given-names></name></person-group><article-title>Intravenous caffeine versus intravenous ketorolac for the management of moderate to severe migraine headache</article-title><source>Bangladesh J Pharmacol</source><year>2016</year><volume>11</volume><fpage>428</fpage><lpage>432</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baratloo</surname><given-names>A</given-names></name><name><surname>Negida</surname><given-names>A</given-names></name><name><surname>El-Ashal</surname><given-names>G</given-names></name><name><surname>Behnaz</surname><given-names>N</given-names></name></person-group><article-title>Intravenous caffeine for the treatment of acute migraine: a pilot study</article-title><source>J Caffeine Res</source><year>2015</year><volume>5</volume><fpage>125</fpage><lpage>129</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawker</surname><given-names>GA</given-names></name><name><surname>Mian</surname><given-names>S</given-names></name><name><surname>Kendzerska</surname><given-names>T</given-names></name><name><surname>French</surname><given-names>M</given-names></name></person-group><article-title>Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)</article-title><source>Arthritis Care Res (Hoboken)</source><year>2011</year><volume>63</volume><issue>Suppl 11</issue><fpage>S240</fpage><lpage>S252</lpage><pub-id pub-id-type="pmid">22588748</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alschuler</surname><given-names>KN</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Ehde</surname><given-names>DM</given-names></name></person-group><article-title>Defining mild, moderate, and severe pain in persons with multiple sclerosis</article-title><source>Pain Med</source><year>2012</year><volume>13</volume><fpage>1358</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">22925457</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelman</surname><given-names>DC</given-names></name><name><surname>Dukes</surname><given-names>E</given-names></name><name><surname>Brandenburg</surname><given-names>N</given-names></name><name><surname>Bostrom</surname><given-names>A</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name></person-group><article-title>Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy</article-title><source>Pain</source><year>2005</year><volume>115</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">15836967</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>AM</given-names></name></person-group><article-title>The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain</article-title><source>Emerg Med J</source><year>2001</year><volume>18</volume><fpage>205</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">11354213</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>BS</given-names></name><name><surname>Wolff</surname><given-names>HG</given-names></name></person-group><article-title>Experimental studies on headache: pain-sensitive structures of the head and their significance in headache</article-title><source>Arch Surg</source><year>1940</year><volume>41</volume><fpage>813</fpage><lpage>856</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Dalessio</surname><given-names>DJ</given-names></name></person-group><source>Wolff's headache and other head pain</source><edition>7th ed</edition><publisher-loc>New York (NY)</publisher-loc><publisher-name>Oxford University Press</publisher-name><year>2001</year><fpage>606</fpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lance</surname><given-names>JW</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><chapter-title>Chapter 8: migraine: pathophysiology</chapter-title><person-group person-group-type="editor"><name><surname>Lance</surname><given-names>JW</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><source>Mechanism and management of headache</source><edition>7th ed</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Elsevier Butterworth-Heinemann</publisher-name><year>2005</year><fpage>87</fpage><lpage>121</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><source>Headache in clinical practice</source><publisher-loc>Oxford</publisher-loc><publisher-name>Isis Medical Media</publisher-name><year>1998</year><fpage>250</fpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>S</given-names></name><name><surname>Bendtsen</surname><given-names>L</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Pathophysiology of migraine and tension-type headache</article-title><source>Tech Reg Anesth Pain Manag</source><year>2012</year><volume>16</volume><fpage>14</fpage><lpage>18</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrobon</surname><given-names>D</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group><article-title>Pathophysiology of migraine</article-title><source>Annu Rev Physiol</source><year>2013</year><volume>75</volume><fpage>365</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">23190076</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Friberg</surname><given-names>L</given-names></name><name><surname>Olsen</surname><given-names>TS</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Lassen</surname><given-names>NA</given-names></name><name><surname>Andersen</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Timing and topography of cerebral blood flow, aura, and headache during migraine attacks</article-title><source>Ann Neurol</source><year>1990</year><volume>28</volume><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">2285266</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolay</surname><given-names>H</given-names></name><name><surname>Reuter</surname><given-names>U</given-names></name><name><surname>Dunn</surname><given-names>AK</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Boas</surname><given-names>DA</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group><article-title>Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">11821897</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name></person-group><article-title>Migraine--current understanding and treatment</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>257</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">11807151</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>SJ</given-names></name></person-group><article-title>Complementary and alternative treatments for childhood headaches</article-title><source>Curr Pain Headache Rep</source><year>2008</year><volume>12</volume><fpage>379</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">18765145</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>FR</given-names></name></person-group><article-title>Nutraceuticals and headache: the biological basis</article-title><source>Headache</source><year>2011</year><volume>51</volume><fpage>484</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">21352223</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaskar</surname><given-names>S</given-names></name><name><surname>Saeidi</surname><given-names>K</given-names></name><name><surname>Borhani</surname><given-names>P</given-names></name><name><surname>Amiri</surname><given-names>H</given-names></name></person-group><article-title>Recent progress in migraine pathophysiology: role of cortical spreading depression and magnetic resonance imaging</article-title><source>Eur J Neurosci</source><year>2013</year><volume>38</volume><fpage>3540</fpage><lpage>3551</lpage><pub-id pub-id-type="pmid">24118449</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Ayata</surname><given-names>C</given-names></name></person-group><article-title>Cortical spreading depression and migraine</article-title><source>Curr Neurol Neurosci Rep</source><year>2010</year><volume>10</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">20425031</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>G</given-names></name><name><surname>Leon</surname><given-names>A</given-names></name></person-group><article-title>Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond</article-title><source>Neurol Sci</source><year>2010</year><volume>31</volume><issue>Suppl 1</issue><fpage>S1</fpage><lpage>S7</lpage><pub-id pub-id-type="pmid">20464574</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name></person-group><article-title>Migraine pain and nociceptor activation--where do we stand?</article-title><source>Headache</source><year>2010</year><volume>50</volume><fpage>909</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">20546325</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group><article-title>Origin of pain in migraine: evidence for peripheral sensitisation</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">19539239</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrobon</surname><given-names>D</given-names></name><name><surname>Striessnig</surname><given-names>J</given-names></name></person-group><article-title>Neurobiology of migraine</article-title><source>Nat Rev Neurosci</source><year>2003</year><volume>4</volume><fpage>386</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">12728266</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunwiddie</surname><given-names>TV</given-names></name><name><surname>Masino</surname><given-names>SA</given-names></name></person-group><article-title>The role and regulation of adenosine in the central nervous system</article-title><source>Annu Rev Neurosci</source><year>2001</year><volume>24</volume><fpage>31</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">11283304</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scher</surname><given-names>AI</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Stewart</surname><given-names>W</given-names></name></person-group><article-title>Risk factors for chronic daily headache</article-title><source>Curr Pain Headache Rep</source><year>2002</year><volume>6</volume><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">12413408</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>C</given-names></name><name><surname>Sakata</surname><given-names>RK</given-names></name></person-group><article-title>Caffeine in the treatment of pain</article-title><source>Rev Bras Anestesiol</source><year>2012</year><volume>62</volume><fpage>387</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">22656684</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>HY</given-names></name><name><surname>Yeh</surname><given-names>TH</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name></person-group><article-title>Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials</article-title><source>Pain Physician</source><year>2016</year><volume>19</volume><fpage>E97</fpage><lpage>E112</lpage><pub-id pub-id-type="pmid">26752497</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolay</surname><given-names>H</given-names></name><name><surname>Ozge</surname><given-names>A</given-names></name><name><surname>Saginc</surname><given-names>P</given-names></name><name><surname>Orekici</surname><given-names>G</given-names></name><name><surname>Ulud&#x000fc;z</surname><given-names>D</given-names></name><name><surname>Yal&#x00131;n</surname><given-names>O</given-names></name><etal/></person-group><article-title>Gender influences headache characteristics with increasing age in migraine patients</article-title><source>Cephalalgia</source><year>2015</year><volume>35</volume><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">25424708</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallerand</surname><given-names>AH</given-names></name><name><surname>Polomano</surname><given-names>RC</given-names></name></person-group><article-title>The relationship of gender to pain</article-title><source>Pain Manag Nurs</source><year>2000</year><volume>1</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11710147</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillingim</surname><given-names>RB</given-names></name><name><surname>King</surname><given-names>CD</given-names></name><name><surname>Ribeiro-Dasilva</surname><given-names>MC</given-names></name><name><surname>Rahim-Williams</surname><given-names>B</given-names></name><name><surname>Riley</surname><given-names>JL</given-names><suffix>3rd</suffix></name></person-group><article-title>Sex, gender, and pain: a review of recent clinical and experimental findings</article-title><source>J Pain</source><year>2009</year><volume>10</volume><fpage>447</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">19411059</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillingim</surname><given-names>RB</given-names></name></person-group><article-title>Sex, gender, and pain: women and men really are different</article-title><source>Curr Rev Pain</source><year>2000</year><volume>4</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10998712</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yezierski</surname><given-names>RP</given-names></name></person-group><article-title>The effects of age on pain sensitivity: preclinical studies</article-title><source>Pain Med</source><year>2012</year><volume>13</volume><issue>Suppl 2</issue><fpage>S27</fpage><lpage>S36</lpage><pub-id pub-id-type="pmid">22497745</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Tumi</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>MI</given-names></name><name><surname>Dantas</surname><given-names>PB</given-names></name><name><surname>Maynard</surname><given-names>MJ</given-names></name><name><surname>Tashani</surname><given-names>OA</given-names></name></person-group><article-title>Age-related changes in pain sensitivity in healthy humans: a systematic review with meta-analysis</article-title><source>Eur J Pain</source><year>2017</year><volume>21</volume><fpage>955</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">28230292</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victor</surname><given-names>TW</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Campbell</surname><given-names>JC</given-names></name><name><surname>Buse</surname><given-names>DC</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Migraine prevalence by age and sex in the United States: a life-span study</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>1065</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">20713557</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>AD</given-names></name><name><surname>McGregor</surname><given-names>JC</given-names></name><name><surname>Perencevich</surname><given-names>EN</given-names></name><name><surname>Furuno</surname><given-names>JP</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Peterson</surname><given-names>DE</given-names></name><etal/></person-group><article-title>The use and interpretation of quasi-experimental studies in medical informatics</article-title><source>J Am Med Inform Assoc</source><year>2006</year><volume>13</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16221933</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Box plot shows minimum, maximum, median and inter-quartile range of pain scores based on visual analogue scale at baseline, 1 hour, and 2 hours after intervention in the two groups of patients (Caffeine citrate vs. Magnesium sulfate).</title></caption><graphic xlink:href="kjpain-30-176-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline Characteristics of Patients</title></caption><graphic xlink:href="kjpain-30-176-i001"/><table-wrap-foot><fn><p><sup>*</sup>Data are presented as mean &#x000b1; standard deviation. VAS: visual analogue scale.</p></fn></table-wrap-foot></table-wrap></floats-group></article>